Search results
Results from the WOW.Com Content Network
Norovirus is surging across the U.S., with case numbers higher now than they've been at the same time in more than a decade, according to the U.S. Centers for Disease Control and Prevention (CDC ...
An ideal norovirus vaccine, Fink says, would not only cover at least 70% to 80% of currently circulating genotypes but also be versatile as genotypes evolve. Moderna is betting on mRNA technology ...
Volunteers in north Wales are among 25,000 people taking part in a global trial to find a vaccine against the symptoms of the winter vomiting bug, norovirus. The virus affects about four million ...
LigoCyte announced in 2007 that it was working on a vaccine and had started phase 1 trials. [66] The company has since been taken over by Takeda Pharmaceutical Company . [ 67 ] As of 2019 [update] , a bivalent (NoV GI.1/GII.4) intramuscular vaccine had completed phase 1 trials.
With norovirus accounting for around 12,000 hospital admissions every year, news that a groundbreaking vaccine trial is set to begin has raised hopes that it could eventually help to relieve the ...
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection.
Expert Review of Vaccines is a monthly peer-reviewed medical journal covering all aspects impacting the clinical effectiveness of vaccines. According to the Journal Citation Reports , the journal has a 2015 impact factor of 4.222.
Science & Tech. Shopping. Sports